HB 695 - AS AMENDED BY THE HOUSE
HOUSE BILL 695
SPONSORS: Rep. McBeath, Rock. 26
COMMITTEE: Commerce and Consumer Affairs
This bill requires nonprofit organizations advocating on behalf of patients or that fund medical research to compile a report relative to payments received from certain manufacturers, insurance carriers, or pharmacy benefit managers. The nonprofit organization shall post the report on its Internet website or file it with the insurance commissioner.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
19Mar2019... 0761h 19-0735
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Nineteen
Be it Enacted by the Senate and House of Representatives in General Court convened:
400-A:30-a Transparency of Nonprofit Patient Advocacy Organizations.
I. In this section, “patient advocacy organization” means any formally organized nonprofit group that primarily concerns itself with medical conditions or potential medical conditions and has a mission and takes actions that seek to help people affected by those medical conditions or to help their families. “Patient advocacy organization” shall not include a professional organization typically focusing on advancing its profession or serving professional members as a primary goal.
II.(a) On or before January 1 of each year, any patient advocacy organization that has received a payment, donation, subsidy or anything else of value from a pharmaceutical manufacturer, health insurance carrier, or pharmacy benefit manager, or a trade or advocacy group for pharmaceutical manufacturers, health insurance carriers, or pharmacy benefit managers during the immediately preceding calendar year shall compile a report which includes:
(1) For each such contribution, the amount of the contribution and the pharmaceutical manufacturer, affiliated third party, pharmacy benefit manager, or group that provided the payment, donation, subsidy or other contribution; and
(2) The percentage of the total gross income of the organization during the immediately preceding calendar year attributable to payments, donations, subsidies, or other contributions from each pharmaceutical manufacturer, health insurance carrier, pharmacy benefit manager, or group.
(b) Except as otherwise provided in this section, the patient advocacy organization shall post the report on its Internet website which is accessible by the public. If the nonprofit organization does not maintain an Internet website that is accessible to the public, the nonprofit organization shall submit the report compiled pursuant to subparagraph (a) to the insurance department.
III. Any patient advocacy organization that has received a payment, donation, subsidy or anything else of value from a pharmaceutical manufacturer, health insurance carrier, or pharmacy benefit manager, or a trade or advocacy group for pharmaceutical manufacturers, health insurance carriers, or pharmacy benefit managers during the immediately preceding calendar year shall disclose that fact when testifying, lobbying, or otherwise engaging in person with a member of the general court.
IV. Any patient advocacy organization that has a paid employee of the organization who is a registered lobbyist with the state of New Hampshire and is wearing a name tag in compliance with RSA 15:2 or otherwise identifies him or herself as a lobbyist shall be exempt from this section.
V. Any patient advocacy organization found in violation of this section may be fined up to $1,000 per violation.
|March 5, 2019||House||Hearing|
|March 8, 2019||House||Exec Session|
|March 8, 2019||House||Exec Session|
|March 19, 2019||House||Floor Vote|
|April 25, 2019||Senate||Hearing|
|April 30, 2019||Senate||Hearing|
|May 7, 2019||Senate||Hearing|
|May 30, 2019||Senate||Floor Vote|
|Jan. 3, 2019||Introduced 01/03/2019 and referred to Commerce and Consumer Affairs HJ 3 P. 26|
|March 5, 2019||Public Hearing: 03/05/2019 10:30 am LOB 302|
|March 6, 2019||Subcommittee Work Session: 03/06/2019 08:30 am LOB 302|
|March 8, 2019||Subcommittee Work Session: 03/08/2019 09:00 am LOB 302-304|
|March 8, 2019||Executive Session: 03/08/2019 01:30 pm LOB 302-304|
|March 19, 2019||Committee Report: Ought to Pass with Amendment # 2019-0761h for 03/19/2019 (Vote 18-2; CC) HC 16 P. 6|
|Committee Report: Ought to Pass with Amendment # 2019-0761h (Vote 18-2; CC)|
|March 19, 2019||Amendment # 2019-0761h: AA VV 03/19/2019 HJ 10 P. 16|
|March 19, 2019||Ought to Pass with Amendment 2019-0761h: MA VV 03/19/2019 HJ 10 P. 16|
|March 28, 2019||Introduced 03/28/2019 and Referred to Commerce; SJ 12|
|April 25, 2019||==RECESSED== Hearing: 04/25/2019, Room 100, SH, 01:00 pm; SC 19|
|April 30, 2019||==RECESSED== Hearing: 04/30/2019, Room 102, LOB, 02:45 pm; SC 20|
|May 7, 2019||==RECONVENE== Hearing: 05/07/2019, Room 100, SH, 01:00 pm; SC 21|
|Committee Report: Inexpedient to Legislate|
|May 30, 2019||Committee Report: Inexpedient to Legislate, 05/30/2019; SC 24|
|May 30, 2019||Inexpedient to Legislate, MA, VV === BILL KILLED ===; 05/30/2019; SJ 18|